Neurizon Therapeutics Limited (ASX: NUZ) announced on 6 October 2026 that it received written feedback from the US Food and Drug Administration (FDA) regarding its investigational treatment, NUZ-001, for amyotrophic lateral sclerosis (ALS). Neurizon, a late-stage clinical biotechnology company advancing treatments for neurodegenerative diseases, is developing NUZ-001 for ALS, the most common form of motor neurone disease. The FDA’s Type C meeting feedback indicates that the ongoing Phase 2/3 HEALEY ALS Platform Trial for NUZ-001 (Regimen I) has the potential to be a registrational study, providing valuable guidance for Neurizon’s regulatory pathway.
The regulatory agency noted that positive results from the placebo-controlled HEALEY ALS Platform Trial, which assesses clinically meaningful endpoints, could support a traditional approval pathway for NUZ-001. Furthermore, the FDA stated the trial may serve as the single registrational study for a New Drug Application (NDA), contingent on meeting requirements for substantial evidence of effectiveness. This guidance aligns with Neurizon’s regulatory strategy and will inform NDA preparation. The FDA also provided input on biomarkers, agreeing with Neurizon’s approach to measuring plasma neurofilament light chain (NfL), with biomarker data intended to form part of the supporting evidence.
Neurizon confirmed Regimen I of the HEALEY trial is fully enrolled, with topline results anticipated in late Q2 CY2027. Dr. Chris Bremer, Chief Executive Officer, stated this feedback offers crucial guidance for the NUZ-001 NDA evidence package, highlighting the FDA’s indication of Regimen I potentially serving as a single registrational study. With the trial fully enrolled, the company’s focus remains on completing the trial and compiling necessary evidence for submission. An NIH-funded NUZ-001 expanded access program is expected in Q1 CY2027, and Neurizon continues to evaluate resubmitting a Fast Track Designation request.
